Stockholm Stock Exchange | Mid Cap
Calliditas
+6.84%
Latest
+26.50%
3 months
Kepler CheuvreuxCarnegieSEBPareto SecuritiesGuggenheim SecuritiesBryan GarnierCiti Investment ResearchKempenSEB Equities

Price Targets For Calliditas

AnalystPrice TargetDateUpside
Kepler Cheuvreux125 SEKFeb 22
+6.84%
Carnegie171 SEKFeb 22
SEB230 SEKJul -23
Pareto Securities230 SEKMay -23
Guggenheim Securities231.05 SEKApr -23
Bryan Garnier190 SEKSep -22
Citi Investment Research384 SEKDec -21
Kempen320 SEKDec -21
SEB Equities75 SEKNov -21

About The Company

Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas